Taysha Gene Therapies Issues Equity Grants to Four New Hires
Taysha awarded RSUs and stock options to four new employees under its 2023 Inducement Plan, per Nasdaq listing rules.
DALLAS — Taysha Gene Therapies, Inc. (Nasdaq: TSHA) disclosed Thursday that its Board of Directors' Compensation Committee approved equity awards for four newly hired employees, effective October 1, 2026, as part of standard inducement compensation tied to their employment agreements.
The grants consist of restricted stock units representing 384,000 shares of Taysha common stock alongside an option to purchase an additional 92,400 shares. The awards were issued under the company's 2023 Inducement Plan, a dedicated equity vehicle separate from the firm's general employee stock plan.
Read more Integer Holdings Opens Conversion Window for 2028 Senior Notes →
The grants were structured to comply with Nasdaq Listing Rule 5635(c)(4), which permits companies to issue equity as a material inducement to prospective employees without requiring prior shareholder approval, provided specific disclosure conditions are met.
Taysha is a clinical-stage biotechnology company concentrating on adeno-associated virus gene therapies targeting severe monogenic diseases of the central nervous system. The hiring activity suggests ongoing expansion of the company's workforce as it advances its CNS pipeline.
Continue reading at GlobeNewswire - Industry News on Financial Services.
